(1S,2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol hydrochloride

• ChemBase编号: 122524
• 分子式: C16H26ClNO2
• 平均质量: 299.83614
• 单一同位素质量: 299.16520676
• SMILES: [C@]1([C@H](CN(C)C)CCCC1)(c1cc(OC)ccc1)O.Cl
• Canonical SMILES: COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C.Cl
• InChI: InChI=1S/C16H25NO2.ClH/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3;/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3;1H/t14-,16+;/m0./s1
• InChIKey: PPKXEPBICJTCRU-KUARMEPBSA-N

名称和登记号

名称

• IUPAC标准名: (1S,2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol hydrochloride
• IUPAC传统名: (1S,2S)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol hydrochloride
• 别名: (1S,2S)-(-)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Hydrochloride; (1S-cis)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Hydrochloride; (-)-(1S,2S)-Tramadol Hydrochloride; E 381; (-)-Tramadol Hydrochloride; (1S,2S)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol hydrochloride; Tramadol Hydrochloride

登记号

• CAS号: 148229-78-1; 148229-79-2
• PubChem SID: 162216877
• PubChem CID: 10017651

理论计算性质

• Acid pKa: 13.7952175
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): -0.8504328
• LogD (pH = 7.4): 0.6215551
• Log P: 2.4498615
• 摩尔折射率: 78.2692 cm^3
• 极化性: 30.83849 Å^3
• 极化表面积: 32.7 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Dichloromethane; Methanol; Water
• 外观: White Solid
• 熔点: 171-172°C

安全信息

• 保存条件: Hygroscopic, -20°C Freezer, Under Inert Atmosphere

药理学性质

• 生物活性机理: Mu-opioid receptor agonist and monoamine reuptake inhibitor

产品相关信息

• 成盐信息: HCl
• 应用领域: Analgesic

详细说明

Toronto Research Chemicals - T712525

An analgesic. Used in the treatment of urinary incontinence.

参考文献

• Raffa, R.B., et al.: J. Pharmacol. Exp. Ther., 267, 331 (1993)
• U.S. Pat., 1972, Chemie Grunenthal, 3 652 589; CA, 76, 153321, (synth, pharmacol)
• Flick, K. et al., Arzneim.-Forsch., 1978, 28, 107, (synth, pharmacol, numerous papers)
• Lintz, W. et al., Arzneim.-Forsch., 1981, 31, 1932, (metab)
• Hanna, G.M. et al., Pharmazie, 1989, 44, 321, (pmr)
• Tsai, R.-S. et al., J. Chem. Res., Synop., 1993, 298; J. Chem. Res., Miniprint, 1993, 1901, (props)
• Elsing, B. et al., J. Chromatogr., 1993, 612, 223, (hplc)
• Dayer, P. et al., Drugs, Suppl. 1, 1994, 47, 3; 1997, 53, 18, (rev, pharmacol)
• Grond, S. et al., Pain, 1995, 62, 313, (pharmacol, enantiomers)
• Frink, M.C. et al., Arzneim.-Forsch., 1996, 46, 1029, (pharmacol, enantiomers)
• Katz, W.A., Drugs, Suppl. 3, 1996, 52, 39, (rev)
• Edkins, T.J. et al., Enantiomer, 1996, 1, 97-107, (enantiomers, hplc)
• Lai, J. et al., Eur. J. Pharmacol., 1996, 316, 369, (pharmacol)
• Paar, W.D. et al., J. Chromatogr., B: Biomed. Appl., 1996, 686, 221, (hplc)
• Merslavic, M. et al., J. Chromatogr., B: Biomed. Appl., 1997, 693, 222, (gc-ms)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 90
• Scott, L.J. et al., Drugs, 2000, 60, 139-176, (rev)
• Itov, Z. et al., Org. Process Res. Dev., 2000, 4, 291-294, (resoln)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, THJ500